Monopar Therapeutics Inc.

NasdaqCM:MNPR Stock Report

Market Cap: US$650.6m

Monopar Therapeutics Management

Management criteria checks 2/4

Monopar Therapeutics' CEO is Chandler Robinson, appointed in Dec 2014, has a tenure of 11.58 years. total yearly compensation is $10.64M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 2.42% of the company’s shares, worth $15.74M. The average tenure of the management team and the board of directors is 5.1 years and 6.3 years respectively.

Key information

Chandler Robinson

Chief executive officer

US$10.6m

Total compensation

CEO salary percentage6.58%
CEO tenure11.6yrs
CEO ownership2.4%
Management average tenure5.1yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Analysis Article • May 07

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Nov 22

Is There An Opportunity With Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 46% Undervaluation?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Monopar Therapeutics fair value estimate is US$168 Current...
Seeking Alpha • Oct 10

Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted

Summary Monopar Therapeutics has surged nearly 2,000% in a year, driven by the acquisition of ALXN-1840 and positive MNPR-101-Zr data. ALXN-1840, acquired from AstraZeneca, targets Wilson disease with an NDA filing anticipated in early 2026, but approval remains uncertain. MNPR's radiopharmaceutical pipeline is in early stages, with limited data and no clear timeline for further results. An analysis around this remarkable biotech comeback story follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Mar 04

Monopar Therapeutics: Strong Data, But There Are Risks

Summary Monopar Therapeutics' lead asset, ALXN1840, shows superior copper mobilization in Wilson Disease compared to standard care, with positive phase 3 trial results. The market for Wilson Disease treatments is small, with limited pricing power due to existing generic therapies. Financially, Monopar has a cash runway until 2026 but will need additional funds for commercialization efforts. Key risks include the need for future funding and competition from Pfizer's gene therapy, VTX-801, which is still years from market. Read the full article on Seeking Alpha
Analysis Article • Aug 13

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Feb 27

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 02

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 16

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 05

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Monopar Therapeutics (NASDAQ:MNPR) said it completed enrollment in the phase 2b portion of a phase 2b/3 trial of Validive to treat severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer. Oral mucositis — swelling/irritation in the mouth — is a common, debilitating complication of cancer treatments, mainly chemotherapy and radiation. Monopar said in an Oct. 5 release that it enrolled more than 130 patients, activated 68 sites, expanded the trial to include sites in Germany and Poland, and began enrollment for the phase 3 portion of the trial, dubbed VOICE. Interim analysis of data from the phase 2b part, expected to be reported in Q1 2023, will be used to decide whether to continue enrolling in the phase 3 portion of the trial, the company added. MNPR +18.82% to $2.02 premarket Oct. 5
Analysis Article • Jul 30

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 28

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jul 15

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Mar 26

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO Compensation Analysis

How has Chandler Robinson's remuneration changed compared to Monopar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$15m

Dec 31 2025US$11mUS$700k

-US$14m

Sep 30 2025n/an/a

-US$19m

Jun 30 2025n/an/a

-US$17m

Mar 31 2025n/an/a

-US$17m

Dec 31 2024US$1mUS$603k

-US$16m

Sep 30 2024n/an/a

-US$6m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$2mUS$580k

-US$8m

Sep 30 2023n/an/a

-US$9m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$2mUS$550k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$10m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$1mUS$525k

-US$9m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$2mUS$504k

-US$6m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019US$541kUS$386k

-US$4m

Compensation vs Market: Chandler's total compensation ($USD10.64M) is above average for companies of similar size in the US market ($USD3.54M).

Compensation vs Earnings: Chandler's compensation has increased whilst the company is unprofitable.

CEO

Chandler Robinson (42 yo)

11.6yrs
Tenure
US$10,637,820
Compensation

Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Starr
Co-Founder & Independent Executive Chairman of the Board11.6yrsUS$536.72k0.22%
$ 1.5m
Chandler Robinson
Co-Founder11.6yrsUS$10.64m2.42%
$ 15.7m
Quan Vu
CFO, Principal accounting officer1.3yrsUS$2.16m0.033%
$ 215.7k
Andrew Cittadine
Chief Operating Officer5.1yrsUS$4.71m0.83%
$ 5.4m
Patrice Rioux
Acting Chief Medical Officer9.6yrsno datano data
Susan Rodriguez
Chief Commercial & Strategy Officerless than a yearno datano data
5.1yrs
Average Tenure
59yo
Average Age

Experienced Management: MNPR's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Starr
Co-Founder & Independent Executive Chairman of the Board11.6yrsUS$536.72k0.22%
$ 1.5m
Chandler Robinson
Co-Founder11.6yrsUS$10.64m2.42%
$ 15.7m
Raymond Anderson
Independent Director9.3yrsUS$409.22k0.080%
$ 521.8k
Kim Tsuchimoto
Director3.3yrsUS$389.94k0.17%
$ 1.1m
Lavina Talukdar
Independent Director1.4yrsUS$225.33k0.21%
$ 1.4m
Nicole Sweeny
Independent Directorless than a yearno datano data
6.3yrs
Average Tenure
57.5yo
Average Age

Experienced Board: MNPR's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 22:00
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Monopar Therapeutics Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Brian Kemp DolliverBrookline Capital Markets
Suranjit MukherjeeBTIG